We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.07% | 97.27 | 97.91 | 97.07 | 97.75 | 1,045,674 | 01:00:00 |
From May 2021 to May 2024
By Cristina Roca
Novartis AG said late Friday that the U.S. Food & Drug Administration has approved Scemblix for two indications in chronic myeloid leukemia.
The Swiss pharmaceutical company said the treatment received accelerated approval for one indication and full approval for a second indication. This means continued approval for the first indication may be contingent on confirmatory evidence.
Write to Cristina Roca at cristina.roca@wsj.com
(END) Dow Jones Newswires
November 01, 2021 02:20 ET (06:20 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
